比较挽救性手术后两种再程放疗方法的随机试验:每日一次分段放疗联合同期化疗对比每日两次放疗联合西妥昔单抗治疗头颈部鳞状细胞癌
这项随机试验纳入既往照射区域复发或第二原发头颈部鳞状细胞癌患者,比较VP组(60 Gy/11周,同期5-FU+羟基脲)与HFR组(60 Gy,1.2 Gy每日两次/5周,联合西妥昔单抗),主要终点为治疗中断>15天。VP组26例中1例因毒性中断>15天,HFR组27例中0例;两组总生存无显著差异(中位37.4个月 vs 21.9个月,p=0.12),毒性和无病生存无差异。
要点
- HFR组(60 Gy,1.2 Gy每日两次/5周,联合西妥昔单抗)耐受性可,无患者因毒性中断>15天。
- VP组26例中1例因毒性中断>15天,8/26例化疗延迟和/或减量。
- 两组总生存无显著差异(中位37.4个月 vs 21.9个月,p=0.12),毒性和无病生存无差异。
核心结论
- 每日两次再程放疗60 Gy/5周联合西妥昔单抗方案耐受性可,两组治疗中断无显著差异。
研究设计与样本
- 随机试验,纳入既往照射区域复发或第二原发头颈部鳞状细胞癌患者,VP组26例,HFR组27例。
主要发现
- VP组1例因毒性中断>15天,HFR组0例。
- 两组所有患者均接受至少60 Gy。
- VP组8/26例化疗延迟和/或减量;HFR组4/27例西妥昔单抗<6周期。
- 中位总生存VP组37.4个月 vs HFR组21.9个月(p=0.12),无显著差异。
- 两组毒性和无病生存无差异。
关键数值与推荐
- VP组方案:60 Gy/11周,同期5-FU+羟基脲。
- HFR组方案:60 Gy(1.2 Gy每日两次)/5周,联合西妥昔单抗。
- 主要终点:治疗中断>15天(急性毒性)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: A previous randomized trial in recurrent Head and Neck squamous-cell carcinoma (HNSCC) has shown re-irradiation combined with chemotherapy after salvage surgery significantly improved disease-free survival (DFS). The objective of this randomized trial was to compare two methods of re-irradiation in terms of toxicity and survival. PATIENTS AND METHODS: Patients with recurrence/second primary in previously irradiated area were randomly allocated to receive either 60 Gy over 11 weeks with concomitant 5FU - hydroxyurea (VP-arm), or 60 Gy (1.2 Gy twice daily) over 5 weeks with cetuximab (HFR-arm). Primary endpoint was treatment interruption >15 days (acute toxicity). RESULTS: Twenty-six patients were included in VP-arm and 27 in HFR-arm. One patient in VP-arm experienced >15 days interruption due to toxicity, and none in HFR-arm. In both arms, all patients received at least 60 Gy. In VP-arm, 8/26 patients had chemotherapy delay and/or dose reduction. In HFR-arm, 4/27 patients had <6 cycles cetuximab. There was no significant difference in overall survival (Median OS: 37.4 months vs 21.9 months, p = 0.12). Toxicities and DFS were not different between 2 arms. CONCLUSIONS: Twice daily schedule of re-irradiation of 60 Gy/5 weeks with cetuximab was tolerable and no significant difference in treatment delays occurred between two arms.
引用
- Tao Y, Faivre L, Laprie A, et al. Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab. Radiother Oncol. 2018. PMID: 29784451. doi:10.1016/j.radonc.2018.05.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。